{"id":746492,"date":"2023-04-11T07:33:18","date_gmt":"2023-04-11T11:33:18","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-14\/"},"modified":"2023-04-11T07:33:18","modified_gmt":"2023-04-11T11:33:18","slug":"bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-14","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-14\/","title":{"rendered":"BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)"},"content":{"rendered":"
\n

PALO ALTO, Calif., April 11, 2023 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (\u201cBridgeBio\u201d or the \u201cCompany\u201d), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on April 7, 2023, the compensation committee of BridgeBio\u2019s board of directors granted 11 new employees restricted stock units for an aggregate of 134,300 shares of the Company\u2019s common stock. All of the above-described awards were made under BridgeBio\u2019s 2019 Inducement Equity Plan (the Plan).<\/p>\n

The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio\u2019s board of directors in November 2019 and has been amended and restated from time to time.<\/p>\n

\n About BridgeBio Pharma, Inc.<\/strong>
\n
BridgeBio Pharma, Inc. (BridgeBio) is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio\u2019s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com<\/strong><\/a> and follow us on\u00a0LinkedIn<\/strong><\/a>\u00a0and\u00a0Twitter<\/strong><\/a>.<\/p>\n

\n BridgeBio Contact:<\/strong>
\n
Vikram Bali
contact@bridgebio.com<\/a>
<\/a>(650)-789-8220<\/p>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

PALO ALTO, Calif., April 11, 2023 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (\u201cBridgeBio\u201d or the \u201cCompany\u201d), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on April 7, 2023, the compensation committee of BridgeBio\u2019s board of directors granted 11 new employees restricted stock units for an aggregate of 134,300 shares of the Company\u2019s common stock. All of the above-described awards were made under BridgeBio\u2019s 2019 Inducement Equity Plan (the Plan). The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio\u2019s board of … <\/p>\n

Continue reading “BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-746492","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-14\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PALO ALTO, Calif., April 11, 2023 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (\u201cBridgeBio\u201d or the \u201cCompany\u201d), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on April 7, 2023, the compensation committee of BridgeBio\u2019s board of directors granted 11 new employees restricted stock units for an aggregate of 134,300 shares of the Company\u2019s common stock. All of the above-described awards were made under BridgeBio\u2019s 2019 Inducement Equity Plan (the Plan). The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio\u2019s board of … Continue reading "BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-14\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-11T11:33:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNDk2NSM1NTE4Mzc5IzIxNTY5MjY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-14\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-14\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)\",\"datePublished\":\"2023-04-11T11:33:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-14\\\/\"},\"wordCount\":241,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-14\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwNDk2NSM1NTE4Mzc5IzIxNTY5MjY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-14\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-14\\\/\",\"name\":\"BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-14\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-14\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwNDk2NSM1NTE4Mzc5IzIxNTY5MjY=\",\"datePublished\":\"2023-04-11T11:33:18+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-14\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-14\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-14\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwNDk2NSM1NTE4Mzc5IzIxNTY5MjY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgwNDk2NSM1NTE4Mzc5IzIxNTY5MjY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-14\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-14\/","og_locale":"en_US","og_type":"article","og_title":"BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","og_description":"PALO ALTO, Calif., April 11, 2023 (GLOBE NEWSWIRE) — BridgeBio Pharma, Inc. (Nasdaq: BBIO) (\u201cBridgeBio\u201d or the \u201cCompany\u201d), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced that on April 7, 2023, the compensation committee of BridgeBio\u2019s board of directors granted 11 new employees restricted stock units for an aggregate of 134,300 shares of the Company\u2019s common stock. All of the above-described awards were made under BridgeBio\u2019s 2019 Inducement Equity Plan (the Plan). The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio\u2019s board of … Continue reading \"BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-14\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-11T11:33:18+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNDk2NSM1NTE4Mzc5IzIxNTY5MjY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-14\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-14\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)","datePublished":"2023-04-11T11:33:18+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-14\/"},"wordCount":241,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-14\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNDk2NSM1NTE4Mzc5IzIxNTY5MjY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-14\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-14\/","name":"BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-14\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-14\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNDk2NSM1NTE4Mzc5IzIxNTY5MjY=","datePublished":"2023-04-11T11:33:18+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-14\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-14\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-14\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNDk2NSM1NTE4Mzc5IzIxNTY5MjY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgwNDk2NSM1NTE4Mzc5IzIxNTY5MjY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/bridgebio-pharma-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-14\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/746492","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=746492"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/746492\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=746492"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=746492"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=746492"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}